News & Blog

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy (SUNRISE-FA 2)

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia (FORWARD-FA)

Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich’s Ataxia (PROVE-FA)

Effects of Aerobic Training on Friedreich’s Ataxia

A Study of SGT-212 Gene Therapy in Friedreich’s Ataxia (FALCON)

A Multiple Ascending Dose Study of DT-216P2 in Patients with Friedreich’s Ataxia

An Open Label Study of Nomlabofusp in Subjects With Friedreich’s Ataxia

Phase 1 Clinical Trial of an Investigational Gene Therapy for Cardiac Disease Associated with Friedreich’s Ataxia – AAVrh.10hFXN

A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants with Friedreich’s Ataxia Aged 2 to 15 Years Old (BRAVE)

NAD+ and Exercise in FA (ExRx in FA) – Nicotinamide Riboside (NR)

Omaveloxolone Dose Finding Study in Children With Friedreich’s Ataxia (BOLD)

Gene Therapy for Cardiomyopathy Associated with Friedreich’s Ataxia – LX2006